drugset / Trial / NCT02139319

Dose-Escalation of Botulinum Toxin in Subjects With Osteoarthritis of the Knee

NCT02139319

Phase 1 Completed 22 enrolled Galderma R&D
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of the study is to evaluate the safety and tolerability of the drug product at each dose level.

Timeline

Start
2014-03
Primary completion
2014-07
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin Protein / enzyme biologic Other

Indications